Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Defends “Functional Equivalence”; AWP Proposal Ready, Scully Says

Executive Summary

The Centers for Medicare & Medicaid Services is sticking to its position that deeming Amgen's Aranesp "functionally equivalent" to Johnson & Johnson's Procrit is the best approach to handling the product under the Hospital Outpatient Prospective Payment System

You may also be interested in...



AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data

The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says

AWP Is Out, “WAMP” Is In, CMS Says; Agency Wants New Rx Pricing Data

The Centers for Medicare & Medicaid Services could develop private-sector sources of drug price information rather than relying on government analyses in determining "widely available market price" for Medicare Part B drugs, a draft proposed rule for reforming the current reimbursement system says

CMS “Functional Equivalence” Standard Targeted In Medicare Bills

CMS would be prohibited from using the Aranesp/ Procrit "functional equivalence" decision as a precedent in future reimbursement rulings under both the House and Senate versions of the Medicare prescription drug bill

Related Content

UsernamePublicRestriction

Register

PS041766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel